Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

BACKGROUND AND PURPOSE: IL-13 is a pleiotropic Th2 cytokine considered likely to play a pivotal role in asthma. Here we describe the preclinical in vitro and in vivo characterization of CAT-354, an IL-13-neutralizing IgG4 monoclonal antibody (mAb), currently in clinical development. EXPERIMENTAL APP...

Descripción completa

Detalles Bibliográficos
Autores principales: May, RD, Monk, PD, Cohen, ES, Manuel, D, Dempsey, F, Davis, NHE, Dodd, AJ, Corkill, DJ, Woods, J, Joberty-Candotti, C, Conroy, LA, Koentgen, F, Martin, EC, Wilson, R, Brennan, N, Powell, J, Anderson, IK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415647/
https://www.ncbi.nlm.nih.gov/pubmed/21895629
http://dx.doi.org/10.1111/j.1476-5381.2011.01659.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415647/
https://www.ncbi.nlm.nih.gov/pubmed/21895629
http://dx.doi.org/10.1111/j.1476-5381.2011.01659.x

Ejemplares similares